1h Free Analyst Time
The hereditary angioedema (HAE) therapeutics market is forecasted to grow by USD 2.19 billion during 2023-2028, accelerating at a CAGR of 10.59% during the forecast period. The report on the hereditary angioedema (HAE) therapeutics market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.Speak directly to the analyst to clarify any post sales queries you may have.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by increasing prevalence of hereditary angioedema, advancements in diagnostic techniques, and growing healthcare infrastructure.
The hereditary angioedema (HAE) therapeutics market is segmented as below:
By End-user
- Hospital pharmacies
- Retail pharmacies
- E-commerce
By Product
- C1-esterase inhibitor
- Bradykinin B2 receptor antagonist
- Kallikrein inhibitor
- Others
By Geographical Landscape
- North America
- Europe
- Asia
- Rest of World (ROW)
The report on the hereditary angioedema (HAE) therapeutics market covers the following areas:
- Hereditary angioedema (HAE) therapeutics market sizing
- Hereditary angioedema (HAE) therapeutics market forecast
- Hereditary angioedema (HAE) therapeutics market industry analysis
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
The report presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.
Table of Contents
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by End-user
7 Market Segmentation by Product
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Opportunity/Restraints
11 Competitive Landscape
12 Competitive Analysis
13 Appendix
List of Exhibits
Executive Summary
The following companies are recognized as the key players in the global hereditary angioedema (HAE) therapeutics market: Adverum Biotechnologies Inc, Arrowhead Pharmaceuticals Inc., Attune Pharmaceuticals Inc., BioCryst Pharmaceuticals Inc., BioMarin Pharmaceutical Inc., CENTOGENE NV, Cipla Inc., CSL Ltd., Diapharma Group Inc., Intellia Therapeutics Inc., Ionis Pharmaceuticals Inc., Pharming Group NV, Sanofi SA, and Takeda Pharmaceutical Co. Ltd..Commenting on the report, an analyst from the research team said: "The latest trend gaining momentum in the market is growing demand for personalized medicine."
According to the report, one of the major drivers for this market is the increasing prevalence of hereditary angioedema.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Adverum Biotechnologies Inc
- Arrowhead Pharmaceuticals Inc.
- Attune Pharmaceuticals Inc.
- BioCryst Pharmaceuticals Inc.
- BioMarin Pharmaceutical Inc.
- CENTOGENE NV
- Cipla Inc.
- CSL Ltd.
- Diapharma Group Inc.
- Intellia Therapeutics Inc.
- Ionis Pharmaceuticals Inc.
- Pharming Group NV
- Sanofi SA
- Takeda Pharmaceutical Co. Ltd.
